CRIS
Permanent URI for this communityhttps://investigadores.udd.cl/handle/123456789/1
Browse
8 results
Search Results
Now showing 1 - 8 of 8
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, Multisite Detection of Tn
<i>1549</i>
-Mediated
<i>vanB</i>
Vancomycin Resistance in Multidrug-Resistant Enterococcus faecalis ST6 in Texas and Florida(2023) ;Shelby R. Simar ;Truc T. Tran ;Kirsten B. Rydell ;Diana PanessoGerman A. Contreras<jats:p> In the United States, <jats:italic>vanB</jats:italic> -mediated resistance in enterococci is rare. We characterized three sequence type (ST) 6, vancomycin-resistant <jats:named-content content-type="genus-species">Enterococcus faecalis</jats:named-content> isolates causing bacteremia in unique patients in spatiotemporally distinct settings. </jats:p>7 1Scopus© Citations 3 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, A liaR Deletion Restores Susceptibility to Daptomycin and Antimicrobial Peptides in Multidrug-Resistant Enterococcus faecalis(2014) ;Jinnethe Reyes ;Diana Panesso ;Truc T. Tran ;Nagendra N. MishraMelissa R. Cruz7 1Scopus© Citations 82 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Antimicrobial Susceptibility Testing for Enterococci(2022) ;Ayesha Khan ;William R. Miller ;Dierdre Axell-House; Cesar A. Arias<jats:p>Enterococci are major, recalcitrant nosocomial pathogens with a wide repertoire of intrinsic and acquired resistance determinants and the potential of developing resistance to all clinically available antimicrobials. As such, multidrug-resistant enterococci are considered a serious public health threat.</jats:p>1Scopus© Citations 57 1 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Novel Strategies for the Management of Vancomycin-Resistant Enterococcal Infections(2019) ;German A. Contreras; Cesar A. Arias1Scopus© Citations 36 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Failure of High-Dose Daptomycin for Bacteremia Caused by Daptomycin-Susceptible Enterococcus faecium Harboring LiaSR Substitutions(2014); ;Nagendra N. Mishra ;Danya Alvarez ;Truc T. TranLorena Diaz13 1Scopus© Citations 57 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Daptomycin for the treatment of bacteraemia due to vancomycin-resistant enterococci(2014); ;Barbara E. MurrayCesar A. Arias12Scopus© Citations 39 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Influence of Minimum Inhibitory Concentration in Clinical Outcomes of Enterococcus faecium Bacteremia Treated With Daptomycin: Is it Time to Change the Breakpoint?(2016) ;Bhavarth S. Shukla ;Samuel Shelburne ;Katherine Reyes ;Mini KambojJessica D. Lewis6 1Scopus© Citations 92 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Influence of Inoculum Effect on the Efficacy of Daptomycin Monotherapy and in Combination with beta-Lactams against Daptomycin-Susceptible Enterococcus faecium Harboring LiaSR Substitutions(2018) ;Razieh Kebriaei ;Seth A. Rice ;Kavindra V. Singh ;Kyle C. StamperAn Q. Dinh<jats:p> <jats:named-content content-type="genus-species">Enterococcus faecium</jats:named-content> isolates that harbor LiaFSR substitutions but are phenotypically susceptible to daptomycin (DAP) by current breakpoints are problematic, since predisposition to resistance may lead to therapeutic failure. Using a simulated endocardial vegetation (SEV) pharmacokinetic/pharmacodynamic (PK/PD) model, we investigated DAP regimens (6, 8, and 10 mg/kg of body weight/day) as monotherapy and in combination with ampicillin (AMP), ceftaroline (CPT), or ertapenem (ERT) against <jats:named-content content-type="genus-species">E. faecium</jats:named-content> HOU503, a DAP-susceptible strain that harbors common LiaS and LiaR substitutions found in clinical isolates (T120S and W73C, respectively). </jats:p>3 1Scopus© Citations 37